İbrahim Halil ÖZEROL, Ana AGEITOS, James E. TALMADGE, Mustafa ŞENOL

Non-Hodgkin lenfomalı hastalarda kemik iliği ve periferik stem cell ürünlerinin interleukin-2'ye cevaplarının karşılaştırılması

İnterlekin-2 (IL-2) 'ye immün cevap, normal periferal kan lökositleri (PBL) ile karşılaştırılınca otolog kemik iliği (BM) ve granülosit-monosit koloni stimülan faktör (GM-CSF) ile mobilize edilmiş periferik stem cell (PSC) ürünlerinde farklıdır. Non-Hodgkin lenfomalı 24 hastadan elde edilen stem cell ürünlerinin IL-2 ile kültürden önce ve 5 gün IL-2 ile birlikte kültür yapılarak hücre prolyferasyoraı incelendi. Bxı çalışmalara göre PSC'in IL-2 tarafından stimüle edilen prolifer atıf cevabı normal PBL'den farklı değilken hem PBL ve BM (p=0.0136) hem de PSC ve BM (p=0.0179) arasındaki fark PBL 'den istatistiki olarak anlamlı derecede farklı idi. Bu sonuçlar, PSC'deki defektif lenfositlerin transplantasyondan önce in vitro IL-2 ile muamele edilmesiiledüzeltilebileceğinigöstermektedir.BunedenlehematolojikrekonstitüsyoniçinPSC transplantasyonu, BM transplantasyonuna üstündür. [Turgut Özal Tıp Merkezi Dergisi 1996;3(2):75-79J

The comparison of the responses of bone marrow and peripheral stem cell products from patients with non-Hodgkin lymphoma to interleukin- 2

The immune response to interleukin-2 (IL-2) differs between autologous bone marrow (BM) and granulocyte-monocyte colony stimulating factor (GM-CSF) mobilized peripheral stem cell (PSC) products as well as compared to normal peripheral blood leukocytes (PBL). Stem cell products from 24 patients with non-Hodgkin's lymphoma (NHL) were examined both before and following 5 days co-incubation with IL-2, and the cell proliferation in response to IL-2 were examined. These studies show that the IL-2 stimulated proliferative response of PSC was not different than observed with normal PBL, but there was statistically significant decrease between not only PBL and BM but also PSC and BM (p=0.0136 and p=0.0179, respectively). As these results show, ex vivo threat of PSC with IL-2 before PSC transplantation is capable of to increase defective-lymphocyte function. Therefore, the use of PSC transplantation as compared to BM transplantation for hematologic reconstitution is superior. [Journal of Turgut Özal Medical Center 1996;3(2):75-79J

PDF

___

1. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation (First of two parts). N Engl J Med 1975; 282:832-43.
2. Anderson KC, Dzik WH. Transfusion medicine in hematopoietic stem cell and solid organ transplantation. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology, Basic Principles and Practice. 2nd ed. Churchill Livingstone, USA 1995;2074-87.
3. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation (Second of two parts). N Engl J Med 1975; 282:895-902.
4. Talmadge JE. The combination of stem cell transplantation and immunotherapy: Future potential. In Vivo 1994; 8(5):675-90.
5. Goldman JR, Carovsky D, Galton DAG. Reversal of blast cell crisis in CGL by transfusion of stored autologous buffy-coat cells. Lancet 1978;1:437.
6. Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71:723.
7. Lasky LC. Hematopoietic reconstitution using progenitors recovered from blood. Transfusion 1989; 29:552.
8. Kessinger A, Armitage JO. The use of peripheral stem cell support of high-dose chemotherapy. Important Adv Oncol 1993:167-75.
9. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: Long-term follow-up in 128 patients. Ann Oncol 1993; 4(9):767-73.
10. Vose JM, Bierman PJ, Anderson JR, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up. Blood 1992; 80(8):2142-8.
11. Joshi SS, Kessinger A, Mann SL, et al. Detection of malignant cells in histologically normal bone marrow using culture techniques. Bone Marrow Transplant 1987; 1(3):303-10.
12. Langenmayer I, Weaver C, Buckner CD, et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15:241-6.
13. Greppo PR, Ahmann G, Katzman JA, et al. Peripheral blood as a source of stem cells in myeloma, abstracted. Blood 1988(suppl);72:243a.
14. Gibson FM, Malkovska V, Myint AA, et al. Mechanism of suppression of normal hematopoietic activity by lymphokineactivated killer cells and their products. Exp Hematol 1991; 19:659-73.
15. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69:369-80.
16. Lum LG, Ueda M. Immunodeficiency and the role of suppressor cells after human bone marrow transplantation. Clin Immunol Immunopathol 1992; 63:103-9.
17. Talmadge JE, Reed EC, Kessinger A, et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17:101-9.
18. Smith KA. Interleukin-2: Inception, impact, and implications. Science 1988; 240:1169-76.
19. Kessinger A, Vose JM, Bierman PJ, Bishop M, Armitage JO. Peripheral stem cell transplantation in non-Hodgkin’s lymphoma patients. J Hematother 1993; 2(3):361-2.
20. El-Haddad SI, El-Ashmawy S, Hassan W, et al. Immune deficiency in Hodgkin and non-Hodgkin lymphoma. Biomedicine 1980; 32:128-33.
21. Vose JM, Anderson JR, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 1993; 11(10):1846-51.
22. Gratwohl A, Hermans J, Baldomero H. Hematopoietic precursor cell transplantation in Europa: Activity in 1994. Report from the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17:137-48.
23. Kessinger A. Utilization of peripheral blood stem cells in autotransplantation. Hematol Oncol Clin North Am 1993; 7(3):535-45.
24. Goldman JM. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-6.
25. Korbling M, Juttner C, Henon P, Kessinger A. Autologous blood stem cell versus bone marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl 1): 144-8.
26. Cervantes F, Shu XO, McGlave PB, et al. Autologous bone marrow transplantation for non-transformed low-grade nonHodgkin’s lymphoma. Bone Marrow Transplant 1995; 16:387-92.
27. Brada M, Mizutani S, Molgaard H, et al. Circulating lymphoma cells in patients with B & T non-Hodgkin’s lymphoma detected by immunoglobulin and T-cell receptor gene rearrangement. Br J Cancer 1987; 56:147-52.
28. Bell AJ, Figes A, Oscier DG, Hamblin TJ. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients. Br J Haematol 1987; 66: 63-8.
29. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-33.